Abstract:Background: CD38 and CD47 are expressed in many hematologic malignancies, including multiple myeloma (MM), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and B-cell chronic lymphocytic leukemia (CLL). Here, we evaluated the antitumor activities of CD38/CD47 bispecific antibodies (BsAbs). Methods: Five suitable anti-CD38 antibodies for co-targeting CD47 and CD38 BsAb were developed using a 2 + 2 "mAb-trap" platform. The activity characteristics of the CD38/CD47 BsAbs were evaluated using in vitro and in vivo systems. Results: Using hybridoma screening technology, we obtained nine suitable anti-CD38 antibodies. All anti-CD38 antibodies bind to CD38 + tumor cells and kill tumor cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Five anti-CD38 antibodies (4A8, 12C10, 26B4, 35G5, and 65A7) were selected for designing CD38/CD47 BsAbs (IMM5605) using a "mAb-trap" platform. BsAbs had higher affinity and binding activity to the CD38 target than those to the CD47 target, decreasing the potential on-target potential and off-tumor effects. The CD38/CD47 BsAbs did not bind to RBCs and did not induce RBC agglutination; thus, BsAbs had much lower blood toxicity. The CD38/CD47 BsAbs had a greater ability to block the CD47/SIRPα signal in CD38 + /CD47 + tumor cells than IMM01 (SIRPα Fc fusion protein). Through Fc domain engineering, CD38/CD47 BsAbs were shown to kill tumors more effectively by inducing ADCC and ADCP. IMM5605–26B4 had the strongest inhibitory effect on cellular CD38 enzymatic activity. IMM5605–12C10 had the strongest ability to directly induce the apoptosis of tumor cells. The anti-CD38 antibody 26B4 combined with the SIRPα-Fc fusion proteins showed strong antitumor effects, which were better than any of the mono-therapeutic agents used alone in the NCI-H929 cell xenograft model. The CD38/CD47 BsAbs exhibited strong antitumor effects; specifically, IMM5605–12C10 efficiently eradicated all established tumors in all mice. Conclusion: A panel of BsAbs targeting CD38 and CD47 developed based on the "mAb-tarp" platform showed potent tumor-killing ability in vitro and in vivo . As BsAbs had lower affinity for binding to CD47, higher affinity for binding to CD38, no affinity for binding to RBCs, and did not induce RBC agglutination, we concluded that CD38/CD47 BsAbs are safe and have a satisfactory tolerability profile.

Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment

Recent advances and challenges of bispecific antibodies in solid tumors

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Insights into CD47/SIRPα Axis-Targeting Tumor Immunotherapy

Deciphering the role of CD47 in cancer immunotherapy

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

The landscape overview of CD47-based immunotherapy for hematological malignancies

Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials